Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
Status:
Recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to evaluate the
safety, tolerability, and efficacy of selinexor in combination with R-CHOP (rituximab,
cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance
for untreated EBV-positive diffuse large B-cell lymphoma (DLBCL) patients.